Ovarian Cancer – New Hypothesis Points to Potential Treatment

A laboratory study published in Clinical Cancer Research offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.

The study is the first to show that the natural stiffening of the ovaries called fibrosis occurs with age. It also suggests that the diabetes drug metformin may be able to halt this process. “Fibrosis happens when body tissues are repeatedly injured and inflamed, leaving behind hard collagen fibers that pile up over time, like a scar on the skin,” says Dr. Curtis McCloskey, the lead author. “Cancer cells tend to like growing in these fibrotic tissues.”

Ovarian cancer is the fifth most common cancer in women, and among the deadliest, with a five-year survival rate of 45 percent. Women who have a family history of ovarian cancer or a mutation of the BRCA gene are at greatest risk of the disease. There is no reliable screening test to catch this cancer early. The only options for prevention are birth control pills, which reduce the risk of ovarian cancer by half, or removing the ovaries and fallopian tubes.

The team found that fibrosis of the ovaries is a normal part of aging, usually appearing after menopause. During his research, McCloskey was surprised to find an ovary from a 69-year-old woman that had no fibrosis. Medical records showed she had been taking metformin, a drug for Type 2 diabetes. A Taiwanese study had previously noted an 82 percent reduction of ovarian cancer rates among Type 2 diabetes patients taking metformin.

The research team performed a series of experiments to investigate the links between ovarian fibrosis, aging and metformin. First, they wanted to know what was causing the fibrosis. They thought the answer might lie in ovulation. Every time an ovary releases an egg it becomes inflamed, creating a monthly cycle of wound and repair.

To test this theory, the team used a drug that prevents mice from ovulating. The treated mice did not develop ovarian fibrosis with age, which suggested that ovulation might be linked to the development of fibrosis. However, more detailed studies are needed to confirm this finding.

Second, the team examined 27 ovaries that had been removed from women aged 21 to 82. Most of the ovaries from post-menopausal women were fibrotic. Although only five ovaries came from post-menopausal women who were taking metformin, none of these five had evidence of fibrosis.

Taken together, these findings suggest that targeting ovarian fibrosis might be a new option to reduce the risk of ovarian cancer and add rationale for the use of metformin to prevent ovarian cancer.

“This study was about putting two and two together,” says Dr. Vanderhyden, a senior scientist at The Ottawa Hospital and professor and Corinne Boyer Chair in Ovarian Cancer Research at the University of Ottawa. “Now we’re doing more research to learn how fibrosis develops in the ovaries, and how metformin stops it from happening.”

The findings will need to be confirmed in more mouse models and human ovaries before clinical trials can start. A non-invasive test that can measure fibrosis in the ovary would also need to be created.

“We hope that someday metformin may prove to be an effective preventative treatment for younger women who are at high risk of ovarian cancer, but who can’t remove their ovaries because they still want to have children,” says Vanderhyden.

Reference

McCloskey et al. (2019). Metformin abrogates age-associated ovarian fibrosis. Clinical Cancer Research. DOI: https://doi.org/10.1158/1078-0432.CCR-19-0603

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.